

ANTIGENICS INC /DE/
Form 3
May 12, 2008

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB
Number: 3235-0104
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting
Person *

Invus Public Equities, LP
(Last) (First) (Middle)

750 LEXINGTON
AVENUE, 30TH FLOOR

(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Date of Event Requiring
Statement

(Month/Day/Year)
05/10/2008

3. Issuer Name and Ticker or Trading Symbol
ANTIGENICS INC /DE/ [AGEN]

4. Relationship of Reporting
Person(s) to Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
____ Officer ____ Other
(give title below) (specify below)

5. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group
Filing(Check Applicable Line)
____ Form filed by One Reporting
Person
X Form filed by More than One
Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities
Beneficially Owned
(Instr. 4)

3. Ownership
Form:
Direct (D)
or Indirect
(I)
(Instr. 5)

4. Nature of Indirect Beneficial
Ownership
(Instr. 5)

Common Stock

3,533,333

D (2) 30TH FLOOR

Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form displays a
currently valid OMB control number.**

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and
Expiration Date
(Month/Day/Year)

3. Title and Amount of
Securities Underlying
Derivative Security
(Instr. 4)
Title

4. Conversion
or Exercise
Price of
Derivative
Security

5. Ownership
Form of
Derivative
Security:
Direct (D)

6. Nature of Indirect
Beneficial
Ownership
(Instr. 5)

Edgar Filing: ANTIGENICS INC /DE/ - Form 3

	Date Exercisable	Expiration Date	Amount or Number of Shares	or Indirect (I) (Instr. 5)
Common Stock Warrants (right to buy)	07/09/2008	01/09/2018	Common Stock 3,333,333 \$ 3	D (1) (2) Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Invus Public Equities, LP 750 LEXINGTON AVENUE 30TH FLOOR NEW YORK, NY 10022	Â	Â X	Â	Â
Invus Public Equities Advisors, LLC 750 LEXINGTON AVENUE 30TH FLOOR NEW YORK, NY 10022	Â	Â X	Â	Â
Ulys, LLC 750 LEXINGTON AVENUE 30TH FLOOR NEW YORK, NY 10022	Â	Â X	Â	Â
DEBBANE RAYMOND 750 LEXINGTON AVENUE 30TH FLOOR NEW YORK, NY 10022	Â	Â X	Â	Â

Signatures

Invus Public Equities, L.P., By: Invus Public Equities Advisors, L.L.C., its general partner, By: /s/ Raymond Debbane	05/12/2008
____Signature of Reporting Person	Date
Invus Public Equities Advisors, L.L.C., By: /s/ Raymond Debbane	05/12/2008
____Signature of Reporting Person	Date
Ulys, L.L.C., By: /s/ Raymond Debbane	05/12/2008
____Signature of Reporting Person	Date
/s/ Raymond Debbane	05/12/2008
____Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person also owns warrants to purchase 3,333,333 Units, at an exercise price of \$3.00 per Unit. Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock at an exercise price of \$3.00 per share, as adjusted from time to time. The warrants described in this footnote are not currently exercisable and will not become exercisable until the occurrence of certain events with respect to the Issuer, which events are not solely within the control of the Reporting Person, are not

Edgar Filing: ANTIGENICS INC /DE/ - Form 3

related to the passage of time, and are not related to the market price of the Issuer's stock.

This report is filed jointly by Invus Public Equities, L.P., Invus Public Equities Advisors, L.L.C., Ulys, L.L.C. and Raymond Debbane.

The reported securities are owned directly by Invus Public Equities, L.P. Invus Public Equities Advisors, L.L.C. is the general partner of

- (2) Invus Public Equities, L.P. Ulys, L.L.C. is the managing member of Invus Public Equities Advisors, L.L.C. Raymond Debbane is the sole member of Ulys, L.L.C. Accordingly, each of Invus Public Equities Advisors, L.L.C., Ulys, L.L.C. and Raymond Debbane may be deemed to be indirect beneficial owners of the reported securities. Each of Invus Public Equities Advisors, L.L.C., Ulys, L.L.C. and Raymond Debbane disclaims beneficial ownership of the reported securities, except to the extent of its or his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.